Research programme: peptide deformylase inhibitors - Oscient/Vernalis

Drug Profile

Research programme: peptide deformylase inhibitors - Oscient/Vernalis

Alternative Names: Metalloenzyme inhibitors - Oscient/Vernalis; Peptide deformylase inhibitors - British Biotech/GeneSoft Pharmaceuticals

Latest Information Update: 16 Aug 2010

Price : $50

At a glance

  • Originator Vernalis
  • Developer Oscient Pharmaceuticals; Vernalis
  • Class
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 30 May 2007 Preclinical development is ongoing
  • 30 Jun 2004 Compounds from this research programme are available for licensing (http://www.oscient.com)
  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top